表皮生长因子受体酪氨酸激酶抑制剂吉非替尼

被引:14
作者
张艳华
宁华
姜洋
机构
[1] 北京大学临床肿瘤学院
[2] 北京大学临床肿瘤学院 北京
[3] 北京
关键词
吉非替尼; 表皮生长因子受体酪氨酸激酶抑制剂; 非小细胞肺癌;
D O I
暂无
中图分类号
R979.1 [抗肿瘤、抗癌药物];
学科分类号
1007 ;
摘要
吉非替尼(ZD1839,Iressa)是一种表皮生长因子受体酪氨酸激酶抑制剂,通过阻断酪氨酸激酶信号传导通路抑制肿瘤生长。2个大型的Ⅱ期临床试验(IDEAL)证实了其对于晚期非小细胞肺癌具有应用前景,可以改善症状,延长患者的生存期。此外,在对多种恶性实体瘤的Ⅰ期和Ⅱ期临床研究中也初步证实了该药具有抗肿瘤活性。
引用
收藏
页码:947 / 950
页数:4
相关论文
共 7 条
[1]  
Association of human papillomavirus with penile carcinoma: a study using poly merase chain reaction and in situ hybridization. Varma VA,Sancher LMM,Unger ER,et al. Human Pathology . 1991
[2]  
Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 (’Iressa’) in IDEAL 2. Natale RR,Skarin AT,Maddox AM,et al. Proceedings of the American Society of Clinical Oncology . 2002
[3]  
ZD1839 (’Iressa’), a selective oral EGFR-TKI( epidermal growth factor receptor tyro sine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumors: results of a phase 1111111111 trial. Ranson M,Hammond L,Ferry D,et al. Journal of Clinical Oncology . 2002
[4]  
Studies leading to the i dentification of ZD1839( IRESSA) : an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Barker AJ .Gibson KH,Grundy W,et al. Bioorganic and Medicinal Chemistry . 2001
[5]  
Quantitative assay of epidermal growth rceptor in squamous cell lung carcinomas. Gorgoulis V,Aninos D,Mikou P,et al. Anticancer Research . 1992
[6]  
Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Swaisland H,Laight A,Stafford L,et al. Clinical Pharmacokinetics . 2001
[7]  
Detection of human papil lomavirus deoxyribonucleic acid in penile carcinoma by poly-merase chain reaction and in situ hybridization. Iwasawa A,Kumamoto Y,Fujinaga K. Journal d Urologie . 1993